Cargando…

Combination Therapy of Polymyxin B and Amikacin for Community-Acquired Pseudomonas aeruginosa Pneumonia with MODS in a Previously Healthy Patient: A Case Report

BACKGROUND: Pseudomonas aeruginosa (P. aeruginosa) is an uncommon but fatal causative pathogen for community-acquired pneumonia (CAP). Few case reports described the previously healthy individuals with CAP caused by P. aeruginosa. CASE PRESENTATION: A 67-year-old male farmer was referred to our hosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Junyu, Yun, Lu, Zhao, Hong, Li, Xiangpeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327293/ https://www.ncbi.nlm.nih.gov/pubmed/34349524 http://dx.doi.org/10.2147/IDR.S312601

Ejemplares similares

A case report of community-acquired Pseudomonas aeruginosa pneumonia complicated with MODS in a previously healthy patient and related literature review
por: Wang, Tao, et al.
Publicado: (2019)

Community-acquired Pseudomonas aeruginosa-pneumonia in a previously healthy man occupationally exposed to metalworking fluids
por: Ferraz de Campos, Fernando Peixoto, et al.
Publicado: (2014)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
por: Wang, Yuhang, et al.
Publicado: (2022)

Community Acquired Chronic Arthritis due to Pseudomonas aeruginosa in a Previously Healthy Pregnant Woman
por: Yilmaz, Mesut, et al.
Publicado: (2014)

Community‐acquired Pseudomonas aeruginosa pneumonia manifested by bloody pleural effusion in a previously healthy infant: A case report
por: Dong, Chunjuan, et al.
Publicado: (2022)

Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa
por: Farhan, Sara Mahmoud, et al.
Publicado: (2021)

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
por: Motos, Ana, et al.
Publicado: (2023)

Morphological and Bactericidal Effects of Amikacin, Meropenem and Imipenem on Pseudomonas aeruginosa
por: Moghoofei, Mohsen, et al.
Publicado: (2015)

Community-acquired, hospital-acquired, and healthcare-associated pneumonia caused by Pseudomonas aeruginosa
por: Fujii, Ayumi, et al.
Publicado: (2014)

1317. Prevalence of Pseudomonas aeruginosa as the Causative Organism for Community Acquired Pneumonia
por: Haviland, Adam D, et al.
Publicado: (2021)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
por: Tang, Xi-kang, et al.
Publicado: (2022)

The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection
por: Yazdanian, Mohsen, et al.
Publicado: (2022)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

2585. Identification of Risk Factors for Pseudomonas aeruginosa in Patients with Community-Acquired Pneumonia
por: Karajeh, Jenna, et al.
Publicado: (2023)

Genome-scale metabolic modeling of responses to polymyxins in Pseudomonas aeruginosa
por: Zhu, Yan, et al.
Publicado: (2018)

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
por: Molinaro, Mariadelfina, et al.
Publicado: (2018)

Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa
por: Heffernan, Aaron J., et al.
Publicado: (2021)

Molybdate transporter ModABC is important for Pseudomonas aeruginosa chronic lung infection
por: Périnet, Simone, et al.
Publicado: (2016)

In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates
por: Loho, Tonny, et al.
Publicado: (2018)

Young Healthy Patient With Severe COVID-19 and Fulminant Community-Acquired Pseudomonas aeruginosa Pneumonia: A Case Report
por: Kusaka, Yusuke, et al.
Publicado: (2022)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
por: Avent, Minyon L., et al.
Publicado: (2022)

Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination against Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2023)

Integrated metabolomic and transcriptomic analyses of the synergistic effect of polymyxin–rifampicin combination against Pseudomonas aeruginosa
por: Mahamad Maifiah, Mohd Hafidz, et al.
Publicado: (2022)

Necrotizing Pseudomonas aeruginosa Community-Acquired Pneumonia: A Case Report and Review of the Literature
por: Maharaj, Satish, et al.
Publicado: (2017)

Too Much or Too Little Empiric Treatment for Pseudomonas aeruginosa in Community-acquired Pneumonia?
por: Torres, Antoni, et al.
Publicado: (2021)

A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia
por: Wijit, Kingkarn, et al.
Publicado: (2023)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

The predictive potential of different molecular markers linked to amikacin susceptibility phenotypes in Pseudomonas aeruginosa
por: Nageeb, Wedad M., et al.
Publicado: (2022)

Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
por: Lim, Tze-Peng, et al.
Publicado: (2011)

Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa
por: Lin, Yu-Wei, et al.
Publicado: (2019)

Septic shock secondary to an acute necrotizing community-acquired pneumonia with bacteremia due to Pseudomonas aeruginosa
por: Riviere, P., et al.
Publicado: (2019)

In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?
por: Cuba, Gabriel T., et al.
Publicado: (2022)

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
por: Sime, Fekade Bruck, et al.
Publicado: (2016)

Evaluation of Rapid Polymyxin Pseudomonas test in clinical Pseudomonas aeruginosa isolates with various degrees of multidrug resistance
por: Sánchez-López, Javier, et al.
Publicado: (2021)

Fatal Pseudomonas aeruginosa pneumonia in a previously healthy woman was most likely associated with a contaminated hot tub
por: Huhulescu, S., et al.
Publicado: (2011)

A novel antibiotic combination of linezolid and polymyxin B octapeptide PBOP against clinical Pseudomonas aeruginosa strains
por: Huang, Ting, et al.
Publicado: (2022)

Definitive and Indeterminate Pseudomonas aeruginosa Infection in Adults with Community-acquired Pneumonia: A Prospective Observational Study
por: Sando, Eiichiro, et al.
Publicado: (2021)

The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe Pseudomonas aeruginosa pneumonia
por: Li Bassi, Gianluigi, et al.
Publicado: (2016)

Community-Acquired Pseudomonas aeruginosa Meningitis in a Pediatric Patient
por: Cotran-Lenrow, Alexander, et al.
Publicado: (2023)

Intrathecal (intraventricular) polymyxin B in the treatment of patients with meningoencephalitis by Acinetobacter baumanii and Pseudomonas aeruginosa
por: Macedo, SK, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_492f6ctgehvcpephlptf30jg1k